Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSC-EV is an investigational cell-free biologic therapy consisting of extracellular vesicles derived from mesenchymal stem cells (MSCs). Developed by the Third Affiliated Hospital of Sun Yat-Sen University, it is currently being evaluated for the treatment of acute-on-chronic liver failure (ACLF), particularly in patients who have undergone liver transplantation. Unlike direct cell-based therapies, MSC-EVs utilize paracrine mechanisms to deliver therapeutic cargo, such as microRNAs and proteins, to target cells. This approach aims to repair damaged liver tissue, suppress pathological immune responses, and modulate inflammation without the risks of replication or microvascular embolism associated with live cell transplantation. The therapy is designed to be easily stored and administered as a cell-free alternative to traditional stem cell treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MSC-EV (Third Affiliated Hospital, Sun Yat-Sen University).